» Articles » PMID: 3485398

Nifedipine for Postoperative Blood Pressure Control Following Coronary Artery Vein Grafts

Overview
Specialty General Surgery
Date 1986 Mar 1
PMID 3485398
Authors
Affiliations
Soon will be listed here.
Abstract

The drug control of raised blood pressure following coronary artery bypass grafting was studied in 20 patients during the early postoperative period. On a random basis, 10 patients were given intranasal nifedipine and 10 other patients received intranasal saline. If the systolic pressure was raised, it was treated by an infusion of sodium nitroprusside. The systolic pressure abated in those treated with nifedipine so that 7 of the 10 did not require any other treatment in the first hour. The reduction in pressure was accomplished without an increase in heart rate. The requirement for sodium nitroprusside to control the pressure was much less in the first hour postoperatively in the nifedipine treated group and at 4 hours, the effect of nifedipine was still apparent. This study demonstrates that intranasal nifedipine is an effective adjunct for controlling raised blood pressure in the early postoperative period.

References
1.
Malliani A, Brown A . Reflexes arising from coronary receptors. Brain Res. 1970; 24(2):352-5. DOI: 10.1016/0006-8993(70)90118-6. View

2.
Takekoshi N, Murakami E, Murakami H, Matsui S, Masuya K, Nomura M . Treatment of severe hypertension and hypertensive emergency with nifedipine, a calcium antagonistic agent. Jpn Circ J. 1981; 45(7):852-60. DOI: 10.1253/jcj.45.852. View

3.
McIlvaine W, Boulanger M, Maille J, PAIEMENT B, Taillefer J, Sahab P . Hypertension following coronary artery bypass graft. Can Anaesth Soc J. 1982; 29(3):212-7. DOI: 10.1007/BF03007118. View

4.
Spivack C, Ocken S, Frishman W . Calcium antagonists. Clinical use in the treatment of systemic hypertension. Drugs. 1983; 25(2):154-77. DOI: 10.2165/00003495-198325020-00004. View

5.
FOSTER T, Hamann S, Richards V, Bryant P, Graves D, McALLISTER R . Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol. 1983; 23(4):161-70. DOI: 10.1002/j.1552-4604.1983.tb02720.x. View